Core Insights - Inspire Medical Systems, Inc. (INSP) reported an earnings per share (EPS) of 45 cents for Q2 2025, reflecting a year-over-year increase of 40.6% and exceeding the Zacks Consensus Estimate by 104.6% [1][10] - The company's revenues reached $217.1 million in Q2 2025, marking a 10.8% increase year-over-year and surpassing the Zacks Consensus Estimate by 0.9% [2][10] Revenue Analysis - U.S. revenues amounted to $207.2 million, up 10.3% from the same quarter last year, while revenues from all other countries totaled $9.9 million, representing a 23% year-over-year increase [4][5] - The overall revenue growth was attributed to increased market penetration and heightened awareness among physicians and patients regarding the Inspire system, although this was partially offset by capacity constraints among ENT surgeons and delays in therapy adoption by some U.S. patients and physicians [3][10] Margin and Expense Overview - Gross profit for Q2 2025 increased by 9.9% year-over-year to $182.4 million, but the gross margin contracted by 74 basis points to 84% [6][10] - Selling, general, and administrative expenses rose by 20.8% year-over-year to $159.5 million, while research and development expenses decreased by 9.2% to $26.2 million [6] Financial Position - As of the end of Q2 2025, Inspire Medical had cash and cash equivalents and short-term investments totaling $300.9 million, down from $369.2 million at the end of Q1 2025 [8] - The cumulative net cash used in operating activities was $4 million, compared to net cash provided of $8.8 million in the previous year [8] Outlook and Guidance - The company has revised its revenue outlook for 2025 to a range of $900 million to $910 million, down from a previous estimate of $940 million to $955 million [11] - EPS guidance for 2025 has also been lowered to between 40 cents and 50 cents, significantly down from the prior forecast of $2.20 to $2.30 [12] Market Reaction - Following the earnings report, shares of Inspire Medical experienced a decline of nearly 24.9% in pre-market trading [3]